RESEARCH COLLABORATION - BIOMARKERS IN THE FIGHT AGAINST INFECTIOUS DISEASES
I3 - Development of Immunological Assays for Immunomonitoring in the Context of a Viral Vaccination Platform
The company AmVac Research GmbH provides a vector platform
based on a replication deficient viral vector. For the preclinical and clinical development of vector based vaccines it is essential to establish biomarkers that reflect the vaccine induced immune response qualitatively and quantitatively and therefore allow to draw conclusions on the provided protective effects. Such bioassays for the B and T cellular immune response will be developed in this project.
- AmVac Research GmbH
- Technische Universität München